Kodiak Sciences (KOD) Projected to Post Quarterly Earnings on Thursday

Kodiak Sciences (NASDAQ:KOD) is expected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.87) per share for the quarter.

Kodiak Sciences Trading Down 9.1 %

KOD stock opened at $3.20 on Wednesday. Kodiak Sciences has a 1-year low of $2.19 and a 1-year high of $11.60. The firm has a market cap of $168.40 million, a PE ratio of -0.88 and a beta of 2.26. The business’s 50-day moving average price is $5.15 and its two-hundred day moving average price is $5.43.

Analyst Ratings Changes

Separately, Jefferies Financial Group upgraded Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Monday, December 9th.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.